- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RENOVORX Aktie jetzt für 0€ handeln | |||||
| Fr | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| Do | RenovoRx, Inc.: RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer | 96 | GlobeNewswire (Europe) | MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and... ► Artikel lesen | |
| Mi | RenovoRx, Inc.: RenovoRx Announces Clinical Data Supporting the TAMP Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting | 1 | GlobeNewswire (USA) | ||
| 30.01. | Jones Trading stuft RenovoRx mit "Buy" ein - Kurspotenzial von über 700 % | 1 | Investing.com Deutsch | ||
| 30.01. | Jones Trading initiates coverage on RenovoRx stock with Buy rating | 2 | Investing.com | ||
| 28.01. | RenovoRx, Inc.: RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting | 2 | GlobeNewswire (USA) | ||
| 20.01. | RenovoRx, Inc.: RenovoRx Expands RenovoCath Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center | 1 | GlobeNewswire (USA) | ||
| 14.01. | RenovoRx, Inc.: RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026 | 5 | GlobeNewswire (USA) | ||
| 08.01. | RenovoRx, Inc.: RenovoRx To Announce Promising New Clinical Data Using its TAMP Therapy Platform in an Abstract to be Presented at ASCO GI 2026 | 1 | GlobeNewswire (USA) | ||
| 02.01. | RenovoRx, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 19.11.25 | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th | 1 | GlobeNewswire (USA) | ||
| 13.11.25 | RenovoRx, Inc.: RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update | 199 | GlobeNewswire (Europe) | September 30, 2025 Cash and Cash Equivalents at $10 million Revenue Expected to Grow in 2026 and Continue to Offset Cash Burn Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW... ► Artikel lesen | |
| 13.11.25 | RenovoRx, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11.25 | RenovoRx, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | UCLA oncology surgeon joins RenovoRx's scientific advisory board | 1 | Investing.com | ||
| 06.11.25 | RenovoRx, Inc.: RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD | 1 | GlobeNewswire (USA) | ||
| 04.11.25 | RenovoRx, Inc.: RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th | 1 | GlobeNewswire (USA) | ||
| 09.10.25 | RenovoRx adds interventional oncology expert to scientific advisory board | 2 | Investing.com | ||
| 09.10.25 | RenovoRx, Inc.: RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD | 1 | GlobeNewswire (USA) | ||
| 26.09.25 | RenovoRx reports first patient procedure with RenovoCath | 1 | MassDevice |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | BioNTech- und Nvidia-Aktien verkauft, Medline und Alphabet rein: Erste 13F-Filings sind da! | Der britische Vermögensverwalter Baillie Gifford hat als einer der ersten sein 13F-Filing für das 4. Quartal abgegeben. Unter den großen Namen im Portfolio gibt es ein paar spannende Veränderungen.... ► Artikel lesen | |
| MODERNA | 34,650 | -0,07 % | Arbutus jumps on ruling in patent dispute with Moderna | ||
| BIOGEN | 164,25 | +3,79 % | Ihre wichtigsten Termine: Frische Zahlen von Philip Morris, Under Armour, Toyota, Biogen, Societe Generale | © Foto: Hiro Komae/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| ILLUMINA | 101,04 | -0,18 % | Illumina Inc. Q4 Profit Advances | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) released earnings for its fourth quarter that Increases, from the same period last yearThe company's bottom line came in at $334 million, or $2.16... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| VIKING THERAPEUTICS | 23,745 | -1,29 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity | Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed
VK2735 Currently Being Evaluated in... ► Artikel lesen | |
| ATAIBECKLEY | 3,770 | +10,56 % | Psychodelika-Aktien: Sind Bioxyne, Compass Pathways und Atai "the next big thing"? | ||
| TWIST BIOSCIENCE | 40,130 | -3,53 % | These Analysts Increase Their Forecasts On Twist Bioscience After Q1 Results | ||
| OCULAR THERAPEUTIX | 7,700 | -0,80 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| BIOXCEL THERAPEUTICS | 1,298 | +1,25 % | BioXcel Therapeutics kündigt Meilenstein- und Halteprämien für Führungskräfte an | ||
| BRIACELL THERAPEUTICS | 3,480 | -1,69 % | BriaCell Therapeutics Corp.: BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients | 9 of 25 BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT... ► Artikel lesen | |
| VISTAGEN THERAPEUTICS | 0,563 | +11,52 % | Vistagen Therapeutics, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report |
Das Unternehmen RENOVORX INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,990 Euro und damit +4,11 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RENOVORX INC finden Sie auf Wallstreet Online.